Recombinant Abatacept Biosimilar antibody

Catalog No. ABIN7795080

The Mouse Monoclonal anti-Abatacept Biosimilar antibody is suitable to detect Abatacept Biosimilar in samples from Human. It has been validated for FACS and in vivo.

Quick Overview for Recombinant Abatacept Biosimilar antibody (ABIN7795080)

Target: Abatacept Biosimilar

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details

Expression System: Mammalian cells

Purpose: Abatacept Biosimilar

Specificity: The abatacept biosimilar protein specifically binds to the human CD80 (B7-1) with more avidity than to CD86 (B7-2).

Characteristics: Abatacept (trade name Orencia, Bristol-Myers-Squibb), a fusion protein of a Fc fragment (human IgG1 isotype) and the extracellular domain of CTLA-4, can be used to extend graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. Abatacept binds to CD80 (B7-1) with more avidity than to CD86 (B7-2). Abatacept inhibits the costimulation of T cells. Abatacept differs from belatacept (trade name Nulojix) by only 2 amino acids. The CTLA-4 protein is important for T-cell costimulation and selectively blocks the process of T-cell activation.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details

Target: Abatacept Biosimilar

Target Type: Biosimilar